Home LiteratureArticle Details
PMID: 18165631 Published · ppublish English Comment Editorial

Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology ·Vol. 26 ·No. 1 ·2008-01-01 ·Pages 9-10

Kauff ND

Abstract

暂无摘要

MeSH Terms
BRCA1 Protein/genetics BRCA2 Protein/genetics Female Genetic Testing Germ-Line Mutation/genetics Humans Ovarian Neoplasms/drug therapy,genetics Prognosis Survival Rate
Chemicals
BRCA1 Protein BRCA2 Protein
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Kauff Noah D
Article Info
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Abbr.
J Clin Oncol
ISSN
1527-7755
DOI
10.1200/JCO.2007.14.0244
Published
2008-01-01
Pages
9-10
Language
English
Region
United States
NLM ID
8309333
Subset
IM
Corrections
CommentOn
PMID: 18165636
External Links
PubMed source DOI: 10.1200/JCO.2007.14.0244 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2